Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
Company Announcements

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial

Kiora Pharmaceuticals ( (KPRX) ) has issued an update.

Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.

Find detailed analytics on KPRX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyKiora Pharmaceuticals target ajusted to $54 from $6 at Ladenburg
Austin AngeloKPRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App